Xiaoxing Feng Selected Research

ADI PEG20

1/2022	A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma.
10/2021	Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer.
1/2021	Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers.
1/2021	Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.
1/2019	A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma.
6/2017	Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiaoxing Feng Research Topics

Disease

10	Neoplasms (Cancer) 01/2021 - 08/2010
4	Adenocarcinoma 12/2017 - 07/2012
3	Breast Neoplasms (Breast Cancer) 09/2015 - 07/2012
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2021 - 06/2017
2	Disease Progression 11/2020 - 10/2013
2	Malignant Mesothelioma 11/2020 - 06/2017
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Uveal melanoma 01/2022
1	Hypersensitivity (Allergy) 01/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021
1	Mesothelioma 11/2020
1	Coronary Disease (Coronary Heart Disease) 01/2020
1	Heart Diseases (Heart Disease) 01/2020
1	Glioma (Gliomas) 01/2019

Drug/Important Bio-Agent (IBA)

6	ADI PEG20IBA 01/2022 - 06/2017
5	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 06/2017
5	Pemetrexed (MTA)FDA Link 01/2022 - 06/2017
4	Arginine (L-Arginine)FDA Link 10/2021 - 06/2017
4	Argininosuccinate Synthase (Argininosuccinate Synthetase)IBA 01/2021 - 06/2017
3	DNA (Deoxyribonucleic Acid)IBA 09/2015 - 07/2011
2	Biomarkers (Surrogate Marker)IBA 10/2021 - 06/2017
2	CationsIBA 09/2015 - 05/2015
2	Poly Adenosine Diphosphate RiboseIBA 07/2012 - 07/2011
1	EnzymesIBA 10/2021
1	pembrolizumabIBA 01/2021
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021
1	LigandsIBA 11/2020
1	Bevacizumab (Avastin)FDA Link 01/2019
1	Gemcitabine FDA Link 12/2017
1	130-nm albumin-bound paclitaxelIBA 12/2017
1	AmmoniaIBA 06/2017
1	Essential Amino AcidsIBA 06/2017
1	CitrullineIBA 06/2017
1	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2015
1	Estrogen ReceptorsIBA 09/2015
1	Tamoxifen FDA LinkGeneric 09/2015
1	Methylnitronitrosoguanidine (MNNG)IBA 09/2015
1	Estrogens (Estrogen)FDA Link 09/2015
1	pseudolaric acid BIBA 04/2015
1	DiterpenesIBA 04/2015
1	AcidsIBA 04/2015
1	TubulinIBA 04/2015
1	Biological ProductsIBA 10/2013
1	CaspasesIBA 07/2012
1	poly ADP-ribose glycohydrolaseIBA 07/2012
1	Apoptosis Inducing FactorIBA 07/2012
1	Alkylating AgentsIBA 07/2011
1	A-Form DNA (A-DNA)IBA 07/2011
1	Glycoside Hydrolases (Endoglycosidases)IBA 08/2010

Therapy/Procedure

4	Drug Therapy (Chemotherapy) 01/2019 - 07/2012
1	Immunotherapy 01/2022
1	Tai Ji (Tai Chi Chuan) 01/2020
1	Aftercare (After-Treatment) 09/2015
1	Therapeutics 07/2011